Palatin Technologies, Inc.
A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.
Granted 885
Granted 770 · Sold 565
Granted 2.0K
Granted 2.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Spana CarlPresident and CEO, Director · 10 transactions | -96.2% | 64.4K | 885 | — | — |
| Wills Stephen TExecutive VP and CFO/COO · 11 transactions | -96.1% | 63.4K | 770 | — | 565 |
| Dunton Alan WDirector · 2 transactions | -93.7% | 14.1K | 2.0K | — | — |
| Prendergast John K ADirector · 2 transactions | -78.2% | 13.8K | 2.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -565 shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.